Loading…
Cybin D/B/A Helus Pharma is projected to rise to $11.51 by 2027, a +47% move from its current price of $7.82. HELP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $7.53 | $7.83 | $8.14 | +0.12% |
| Aug 4 | $7.42 | $7.84 | $8.28 | +0.25% |
| Aug 5 | $7.34 | $7.85 | $8.40 | +0.37% |
| Aug 6 | $7.27 | $7.86 | $8.50 | +0.49% |
| Aug 7 | $7.21 | $7.87 | $8.58 | +0.62% |
| Aug 8 | $7.16 | $7.88 | $8.67 | +0.74% |
| Aug 9 | $7.11 | $7.89 | $8.74 | +0.87% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.11 | $7.89 | $8.74 | +0.87% |
| Week 2 | $6.88 | $7.96 | $9.21 | +1.74% |
| Week 3 | $6.71 | $8.03 | $9.59 | +2.63% |
| Week 4 | $6.59 | $8.09 | $9.95 | +3.52% |
| Week 5 | $6.48 | $8.17 | $10.28 | +4.41% |
| Week 6 | $6.40 | $8.24 | $10.60 | +5.32% |
| Week 7 | $6.32 | $8.31 | $10.91 | +6.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cybin Inc., doing business as Helus Pharma, is a clinical stage pharmaceutical company focusing on developing therapies to treat various psychiatric and neurological conditions.
It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.
The company is headquartered in Toronto, Canada. Its preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments.
Helus Pharma, trading under the symbol HELP, is Cybin’s branded clinical-stage healthcare asset in the pharmaceutical space.
The current price is $8.10 and the market capitalization is $502.07M, with a rank of 3019.
The forecast points to a bullish price trajectory over the coming years, with 2026 projected to average $8.10 and 2030 to average $15.39, rising further to a 2050 average of $121.41. The 30-day range is $5.97 to $11.00, and key technical levels include a support at $3.87 and resistance at $8.10. The stock exhibits high annualized volatility at 90%.
A major floor 56.4% below — a decisive break under it would weaken the trend.
The nearest floor, 40.3% below — buyers have tended to step in here.
The nearest ceiling, 4.1% above — a clean break opens room to run.
A major ceiling 32.3% above — clearing it would confirm fresh momentum.
Key HELP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HELP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.83 | Sell | $7.84 | Sell |
| MA 10 | $7.76 | Buy | $7.66 | Buy |
| MA 20 | $7.17 | Buy | $7.21 | Buy |
| MA 50 | $5.77 | Buy | $6.33 | Buy |
| MA 100 | $5.43 | Buy | $6.00 | Buy |
| MA 200 | $6.09 | Buy | $6.20 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.99 | Neutral |
| Stoch RSI (14) | 11.12 | Buy |
| CCI (20) | 72.33 | Neutral |
| Williams %R (14) | -19.63 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 20.12 | Buy |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 80.37 | Sell |
| TRIX (15) | 1.52 | Buy |
| Awesome (5,34) | 1.40 | Buy |
| Ultimate (7,14,28) | 57.21 | Neutral |
| Momentum (10) | 0.57 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 7.97 | Sell |
| ADX (14) | 33.15 | Buy |
| ATR (14) | 0.25 | Info |
The 30-day technical picture is bullish.
RSI14 is 80, indicating strong momentum even as the move approaches stretched levels. The price sits above the SMA50 of $5.30 and the SMA200 of $6.02, which supports near-term upside potential.
Within the 30-day window, the range runs from $5.97 to $11.00, with immediate resistance at $8.10 and a support level at $3.87. The current price is $8.10, placing it at the defined resistance on the horizon.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.87 | $7.82 | $11.22 | 0% | Neutral | |
| $8.82 | $11.51 | $16.07 | +47% | Bullish | |
| $9.00 | $12.25 | $18.00 | +57% | Bullish | |
| $9.90 | $13.96 | $21.32 | +79% | Bullish | |
| $11.77 | $17.12 | $27.01 | +119% | Bullish | |
| $12.85 | $19.24 | $31.22 | +146% | Bullish | |
| $17.71 | $27.25 | $45.32 | +248% | Bullish | |
| $20.88 | $32.97 | $56.08 | +322% | Bullish | |
| $19.70 | $31.88 | $55.35 | +308% | Bullish | |
| $20.80 | $34.47 | $61.00 | +341% | Bullish | |
| $34.40 | $63.72 | $121.97 | +715% | Bullish | |
| $71.59 | $159.08 | $340.69 | +19.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.87 | $7.82 | $9.64 | +0.00% |
| September 2026 | $7.05 | $8.45 | $10.48 | +8.01% |
| October 2026 | $7.23 | $8.75 | $11.02 | +3.62% |
| November 2026 | $7.04 | $8.59 | $10.95 | -1.85% |
| December 2026 | $7.09 | $8.71 | $11.22 | +1.37% |
Click any year to see its month-by-month HELP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, HELP could reach as high as $11.22, with a base case around $7.82 and support toward $3.87 — roughly 0% from $7.82. Price action looks broadly range-bound.
Expect HELP to range from $8.82 to $16.07 through 2027. The $11.51 average target implies a +47% move from current prices. That is up +47% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The HELP price prediction for 2028 points to an average of $12.25 (low $9.00, high $18.00) — a potential gain of +57% on today's $7.82. Momentum favours further upside here.
In 2029, HELP is projected to trade between $9.90 and $21.32, averaging $13.96 — a potential gain of +79% from today's $7.82. That is up +14% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Cybin D/B/A Helus Pharma's 2030 outlook centres on $17.12, within a $11.77 to $27.01 range. That is up +23% on the projected 2029 average. That marks a +119% change versus current levels. Momentum favours further upside here.
By 2031, HELP could reach as high as $31.22, with a base case around $19.24 and support toward $12.85 — roughly +146% from $7.82. Buyers look set to stay in control over this stretch.
Expect HELP to range from $17.71 to $45.32 through 2032. The $27.25 average target implies a +248% move from current prices. That is up +42% on the projected 2031 average. Momentum favours further upside here.
The HELP price prediction for 2033 points to an average of $32.97 (low $20.88, high $56.08) — a potential gain of +322% on today's $7.82. Buyers look set to stay in control over this stretch.
In 2034, HELP is projected to trade between $19.70 and $55.35, averaging $31.88 — a potential gain of +308% from today's $7.82. That is -3% versus the projected 2033 average. Momentum favours further upside here.
Cybin D/B/A Helus Pharma's 2035 outlook centres on $34.47, within a $20.80 to $61.00 range. That is up +8% on the projected 2034 average. That marks a +341% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, HELP could reach as high as $121.97, with a base case around $63.72 and support toward $34.40 — roughly +715% from $7.82. Momentum favours further upside here.
Expect HELP to range from $71.59 to $340.69 through 2050. The $159.08 average target implies a +19.3x move from current prices. That is up +150% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in HELP today (≈ 127.877238 HELP) could be worth
$20,342.79
+$19,342.79 (+1934%) by 2050 · US Dollar
Based on the average projected HELP price of $159.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HELPwould be worth at today's price.
$1,000 invested in HELP on Jul 31, 2025 (≈ 130.039011 HELP) would be worth
$1,016.91
+$16.91 (+1.7%) today · 1.02× · US Dollar
Based on a HELP entry price of $7.69 vs. today's $7.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.62 | $1,026.25 | +2.6% |
| 1 month ago | $6.28 | $1,245.22 | +24.5% |
| 3 months ago | $5.15 | $1,518.45 | +51.8% |
| 6 months ago | $6.87 | $1,138.28 | +13.8% |
| 1 year ago | $7.69 | $1,016.91 | +1.7% |
| All time (5.0y) ago | $116.28 | $67.25 | -93.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HELP forecast.
Our base-case forecast reaches $16.00 around 2030.
Implied market cap at $16.00: $991.75M
The multi-year forecast shows a clear bullish path, with rising average prices across the horizon and expanding upside. The 2026 avg is $8.10 with ROI 0% and neutral sentiment, followed by 2027 avg $11.69 with ROI 44.4% and bullish sentiment. By 2030 the avg reaches $15.39 with ROI 90%.
Further out, 2031 shows $16.41 (ROI 102.6%), 2032 $24.59 (ROI 203.6%), 2033 $29.17 (ROI 260.1%), 2034 $26.46 (ROI 226.7%), and 2035 $28.82 (ROI 255.8%), all with bullish sentiment.
The forecast extends to 2040 with an avg of $49.85 (ROI 515.4%) and to 2050 with an avg of $121.41 (ROI 1398.9%). The overall glide path is upward, though these figures are estimates and carry the usual uncertainty and risk inherent in forward-looking projections.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $15.39 with a min of $10.03 and a max of $25.51, and an ROI of 90%.
Forecasts indicate bullish sentiment from 2027 onward, with 2027 avg $11.69 and 2028 avg $11.85, rising to 2030 avg $15.39 and 2040 avg $49.85, then 2050 avg $121.41 and an ROI reaching 1398.9%.
Yes. The max forecast in 2050 is $279.24, implying a potential above $200 within the forecast horizon.
Current price is $8.10 and market cap is $502.07M.
RSI14 is 80, indicating strong momentum. The 30-day range is $5.97 to $11.00, with resistance at $8.10 and support at $3.87.
Cybin D/B/A Helus Pharma Community Discussion
0Share your Cybin D/B/A Helus Pharma price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.